Literature DB >> 20930862

Prostate cancer: A closer look at the initial results from the REDUCE trial.

Peter H Gann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20930862     DOI： 10.1038/nrurol.2010.144

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate.

Authors:  N E Fleshner; M O'Sullivan; W R Fair
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

2.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

3.  How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?

Authors:  R Choo; C Danjoux; G Morton; E Szumacher; L Sugar; S Gardner; M Kim; C M Choo; L Klotz
Journal:  Prostate       Date:  2007-11-01       Impact factor: 4.104

4.  Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

Authors:  Mary W Redman; Catherine M Tangen; Phyllis J Goodman; M Scott Lucia; Charles A Coltman; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2008-05-18

5.  Estimating rates of true high-grade disease in the prostate cancer prevention trial.

Authors:  Paul Pinsky; Howard Parnes; Leslie Ford
Journal:  Cancer Prev Res (Phila)       Date:  2008-05-18

6.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

Review 7.  Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Clin Oncol       Date:  2009-02-24       Impact factor: 44.544

8.  Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.

Authors:  Yael C Cohen; Kenneth S Liu; Norman L Heyden; Alexandra D Carides; Keaven M Anderson; Anastasia G Daifotis; Peter H Gann
Journal:  J Natl Cancer Inst       Date:  2007-09-11       Impact factor: 13.506
  8 in total
  2 in total

1.  Management of urinary incontinence.

Authors:  George A Demaagd; Timothy C Davenport
Journal:  P T       Date:  2012-06

2.  Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.

Authors:  Nur Ozten-Kandaş; Maarten C Bosland
Journal:  J Carcinog       Date:  2011-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.